01—Abstract
Summary
Summary of the 10-Q filed July 23, 2024. Cited figures are marked; the original filing is the authoritative source.
Danaher's Q2 2024 10-Q shows a quarter of weaker organic performance and a heavy capital return.
Sales fell 3.0% year over year to $5.74 billiona, with core sales down 3.5%. Biotechnology was the main drag, with core sales down 7.0% in the quarter and 12.0% year to date, driven by customers destocking bioprocessing inventory. Diagnostics grew core sales 3.0%, and Life Sciences declined 5.5%.
Diluted EPS from continuing operations was $1.22b, versus $1.24 a year earlier, as higher SG&A (including Abcam-related amortization) and lower interest income offset a lower tax rate and improved gross margin. Balance sheet and capital allocation changed sharply. Cash fell from $5.9 billion at year-end 2023 to $2.4 billion, and total debt declined to $17.0 billion from $18.4 billion after the April repayment of the EUR 900 million 2024 Euronotes.
In the quarter the company repurchased about 17.4 million shares for roughly $4.6 billionc, and the board authorized an additional 20 million shares in July 2024. Goodwill and intangibles fell primarily due to foreign currency translation, and accumulated other comprehensive loss widened to $2.6 billion.
Management expects bioprocessing core revenue to decline for full-year 2024 with gradual sequential improvement, and guided the remaining-2024 effective tax rate to about 17.5%d. Investors will focus on whether Biotechnology stabilizes, whether Diagnostics growth continues, and how the much smaller cash position affects future M&A capacity.
02—Key points
Key Highlights
- Total sales fell 3.0% to $5.74 billion in Q2 2024 (core sales -3.5%, acquisitions +2.0%, currency -1.5%); six-month sales were $11.54 billion, down 2.5%.
- Biotechnology core sales fell 7.0% in Q2 and 12.0% year to date, with bioprocessing customers reducing excess inventory; Life Sciences core sales fell 5.5% in Q2 with China weakness, while Diagnostics core sales rose 3.0%.
- Diluted EPS from continuing operations was $1.22 in Q2 2024 versus $1.24 in Q2 2023; six-month diluted EPS was $2.68 versus $2.89.
- Operating margin was 20.3% in Q2 2024 versus 19.7% a year earlier, helped by Diagnostics margin expansion (24.6% vs. 19.0%), but six-month operating margin fell to 21.5% from 22.6%.
- Cash and equivalents dropped to $2.4 billion from $5.9 billion at year-end 2023, reflecting a $4.5 billion share repurchase program and $974 million of net debt repayments.
- Total debt declined to $17.0 billion, and the company was in compliance with all debt covenants; the $5.0 billion revolving credit facility remains undrawn.
- A new 20 million share repurchase authorization was approved on July 22, 2024, in addition to about 2.6 million shares remaining under the prior program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Danaher Corp kept $0.16.
- Revenue$5.74B100.0%
- Cost of revenue−$2.31B40.3%
- Gross profit$3.43B59.7%
- Operating costs−$2.26B39.4%
- Operating income$1.17B20.3%
- Interest, other & tax−$261.0M4.5%
- Net income$907.0M15.8%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 23, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $5.74B$5.91B | −2.9% |
| Cost of Revenue | $2.31B$2.59B | −10.8% |
| Gross Profit | $3.43B$3.32B | +3.3% |
| R&D Expenses | $391.00M$361.00M | +8.3% |
| SG&A Expenses | $1.87B$1.79B | +4.2% |
| Operating Income | $1.17B$1.16B | +0.4% |
| Net Income | $907.00M$1.11B | −18.0% |
| EPS (Basic) | $1.23$1.50 | −18.0% |
| EPS (Diluted) | $1.22$1.49 | −18.1% |
| Shares Outstanding (Basic) | 737.60M737.30M | 0.0% |
| Shares Outstanding (Diluted) | 742.40M744.70M | −0.3% |
05—Questions
Frequently Asked Questions
Why did Danaher's revenue decline in Q2 2024?
Core sales declined 3.5%, driven mainly by Biotechnology, where bioprocessing customers reduced inventory levels and emerging biotech customers managed liquidity. Life Sciences also declined, led by China. Currency translation reduced sales by 1.5%, partially offset by a 2.0% contribution from acquisitions, including Abcam.
How did the Abcam acquisition affect results?
Acquisitions added 2.0% to reported sales in Q2 but diluted operating margin by about 85 basis points in the quarter, driven by higher amortization and lower-margin integration effects. Abcam also added inventory fair-value step-up charges of $25 million in the first half of 2024.
What is the company's outlook for Biotechnology?
Management expects core revenue for the bioprocessing business to decline for full-year 2024, with gradual year-over-year demand improvement through the rest of the year. The company believes large US and European customers have largely finished reducing excess inventory.
How is Danaher using its cash, and what does it mean for liquidity?
Danaher repurchased about 17.4 million shares for roughly $4.6 billion in Q2 and repaid a EUR 900 million note in April using proceeds from the Veralto separation. Cash fell to $2.4 billion, but the company says operating cash flow, cash on hand and its $5.0 billion revolver are sufficient for its cash requirements, and it has a new 20 million share buyback authorization.
What is the expected tax rate for the rest of 2024?
Management expects the effective tax rate for the remainder of 2024 to be about 17.5%, though it could vary with the earnings mix by jurisdiction, stock-compensation tax benefits and discrete items such as tax contingency accruals.
06—Continue